

Viacord's Stem Cell Transplant Overview

Date of Transplant	Disease Treated	Donor Relationship	Recipient Age (yrs.) (\bar{x} 4.5)	Time Stored (months)	Engraftment Time	Cord Volume Collected (mL)	Nucleated Cell Count (X10 ⁸)	Total CD34+ Cells (X10 ⁶)	Storage Method
06/20/1996	Acute Lymphoblastic Leukemia	Sibling	7	3	45 Days	61	7.4	2.4	Cryobag
11/14/1997	Wiscott Aldrich Syndrome	Sibling	3	4	30 Days	158	14.2	9.5	Cryobag
12/24/1997	Acute Myelogenous Leukemia	Sibling	3	<1	13 Days	59	7.1	1.1	Cryobag
06/15/1999	Fanconi Anemia	Sibling	4	8	17 Days	113	15.1	16	Cryobag
02/02/2000	Sickle Cell Anemia	Sibling	8	24	24 Days	105	10.6	2.3	Cryobag
12/14/2000	Thalassemia Major	Sibling	4	23	45 Days	46	6.2	0.37	Cryobag
04/02/2001	Severe Aplastic Anemia	Autologous (Self)	2	20	10 Days	102	14.1	4.9	Cryobag
06/27/2001	Severe Aplastic Anemia	Sibling	10	36	13 Days	87	10.8	5.4	Cryobag
12/11/2001	Neuroblastoma	Autologous (Self)	6	69	57 Days	51	4.1	0.25	Cryobag
04/23/2002	Fanconi Anemia	Sibling	3	16	24 Days	14	1.1	0.01	Cryobag
04/25/2002	Chronic Granulomatous Disease	Sibling	6	11	n.a.1	63	7.2	0.86	Cryobag
08/29/2003	Fanconi Anemia	Sibling	5	80	n.a.2	67	6.9	2.9	Cryobag
01/22/2004	Sickle Cell Anemia	Sibling	3	6	33 Days	45	3.04	1.15	Cryobag
10/29/2004	Ectodermal Dysplasia	Sibling	5	7	14 Days	66	9.65	1.33	Cryobag
01/27/2005	Fanconi Anemia	Sibling	9	6	27 Days	53	3.15	1	Cryobag
03/22/2005	Acute Myelogenous Leukemia	Sibling	4	28	18 Days	80	6.86	5.83	Cryobag
9/28/2005	Sickle Cell Anemia	Sibling	10	12	17 Days	50	3.42	0.56	Cryobag
10/13/2005	Adrenoleukodystrophy	Sibling	0.5	38	Pending*	60	6.96	2.62	Cryobag
12/23/2005	Severe Aplastic Anemia	Sibling	6.5	10	Pending*	48	7.7	10	Cryobag

1 Engraftment occurred with a follow up stem cell transplant using bone marrow from the same sibling. The patient experienced unpredicted autologous hematopoietic recovery.

2 Engraftment occurred with a follow up bone marrow transplant 28 days later from the same sibling.

*Transplant results are not reported until post 100 days after transplant date.


Cord Blood Stem Cell Transplants

Transplant physicians measure transplant success on three factors: Survival Rate (one-year survival), GvHD Rate (Graft versus Host Disease - Acute & Chronic), and Neutrophil Engraft Rate (Neutrophils enable the body to defend against infection).

Viacord Transplant Outcome

	Viacord Transplants* (median)	All Transplants* (median)
Overall Survival Rate	75%	58%
Chronic GvHD Rate	0%	25%
Acute GvHD Rate	18%	41%
Neutrophil Engraft Rate	88%	87%

*Viacord transplants data as of 12-05. All other transplants based on data compiled 07-05. Data on file.



It is well documented that cord blood stem cells from a family member (related) are a superior treatment option to stem cells from an unrelated donor. Related stem cell transplants have twice the success rate of unrelated transplants.


Since 1988, there have been more than 6,000 cord blood stem cell transplants performed. More than 99% of all cord blood stem cell transplants have been performed with cord blood stored in Cryobags. Less than 1% have been performed utilizing cord blood stored in Cryovials.



Viacord's 80:20 Cryobag



Cryovials



*Based on reported data as of 01/12/06

VIACORD QUALITY PRODUCT GUARANTEE: If your child's cord blood unit is used in a stem cell transplant and the cells do not engraft, we will pay \$25,000 to procure an alternative stem cell source if medically indicated.*

VIACORD
A VIACELL COMPANY

*See viacord.com for terms and conditions.